title: Severe cholestasis related to intraconazole for the treatment of onychomycosis.
abstract: We describe a case of prolonged cholestasis temporally associated with the use of itraconazole for onychomycosis. Peak bilirubin level of 32.0 mg/dl was documented approximately 2 months after discontinuation of the patient's itraconazole therapy, with symptoms of cholestasis persisting more than 1 month after the peak in bilirubin. Physicians should be aware of the potential for severe cholestasis associated with itraconazole usage.
authors.affiliation: Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Talwalkar
authors.forename: R E
authors.initials: RE
authors.lastname: Soetikno
authors.forename: D L
authors.initials: DL
authors.lastname: Carr-Locke
authors.forename: C L
authors.initials: CL
authors.lastname: Berg
mesh_terms: D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001663:Bilirubin / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects*; D008111:Liver Function Tests; D008297:Male; D014009:Onychomycosis / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D001663:Bilirubin